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Abstract
Despite many advances in the last decades in
understanding pain, the development of new
analgesic compounds has not followed at the
same pace. The development of more targeted
analgesic compounds with fewer side effects is
therefore essential. With an increased demand
to demonstrate pharmacodynamic effects of
new analgesic compounds, the importance of
human evoked pain models is now higher than
ever.
Pharmacodynamic evaluation with human
evoked pain models offers the possibility to
determine the dose ranges at which new anal-
gesics exert their pharmacological effect. Pain
models may also aid in the choice of target
population, determine which modality of pain
a new drug is expected to be most suitable, help
to differentiate between a central or more
peripheral mode of action of new drugs, and
help determine which other effects contribute
to its mode of action, e.g., sedation.
Human evoked pain models are conducted
in standardized laboratories where factors like
P. Siebenga · P. Okkerse · G. van Amerongen · R.J. Doll ·
A. Mentink · J. Hay · G.J. Groeneveld (*)





# Springer International Publishing AG 2018
F.J. Hock, M.R. Gralinski (eds.), Drug Discovery and Evaluation: Methods in Clinical Pharmacology,
https://doi.org/10.1007/978-3-319-56637-5_56-1
1
stimulus intensity, frequency, duration, and
location can be controlled. Using pain models
in healthy volunteers has important advantages
over assessing the effects of new drugs in
patients with pain; the pain elicited in human
pain models is predictable in its intensity while
clinical pain will naturally fluctuate. Analgesic
properties can be investigated with pain
models without the influence of accompanying
symptoms that are often seen in patients with
pain.
General Introduction
Pain is intended as a warning to the body that a
noxious stimulus can (potentially) harm the body.
The International Association for the Study of
Pain (IASP) defines pain as an unpleasant sensory
and emotional experience associated with actual
or potential tissue damage or described in terms of
such damage (Bonica 1979). Prevalence studies
show that in Western countries 19–31% of the
adult population suffers from a form of chronic
pain (Macfarlane et al. 2013; Moore et al. 2015).
Despite the availability of potent analgesics such
as opioids, chronic pain remains a high unmet
medical need as many effective analgesics have
important side effects and chronic treatment with
opioids leads to tolerance and addiction. The
development of better and more specific analgesic
compounds therefore remains essential. With an
increased demand to demonstrate pharmacody-
namic effects of new compounds as early as pos-
sible in clinical drug studies, the importance of
human evoked pain models is now more than
ever.
In a pure neurophysiological sense, nocicep-
tive pain occurs when nociceptors are stimulated
by noxious stimuli (e.g., mechanical, thermal,
electrical, or chemical stimuli). After a threshold
has been reached, the nociceptive nerve fiber
transmits the pain signal to the spinal cord. The
signal is modulated at several locations along
ascending pathways through the dorsal horn and
spinal cord. From the spinal cord, the pain signal
is projected to supraspinal centers where the brain
can modulate the excitatory activity via
descending control (Olesen et al. 2012). Percep-
tion of pain is even more complex where more
than one sensory system is responsible for trans-
mission of the painful stimulus (Aguggia 2003).
From a more neuropsychosocial point of view,
pain is a complex experience influenced by many
factors such as emotion, fear, anxiety, but also
cultural background, sex, genetics, and educa-
tional background. Due to its complexity, it can
be difficult to assess the effects of analgesic drugs
on pain in patients, and animal pain models dem-
onstrate low predictability for clinical efficacy in
humans. Several explanations are receptor dissim-
ilarity between species, differences in pharmaco-
kinetics, and morphological and functional
differences between the brains of animals and
humans (Olesen et al. 2012). Human evoked
pain models can control some of these influencing
factors. Therefore, these models are an important
step in the translation of animal research to pain
patients.
Pharmacodynamic evaluation through human
evoked pain models offers the possibility to dif-
ferentiate between a centrally or peripherally act-
ing drug, for which modality of pain a new drug
will be most suitable (nociceptive, neuropathic, or
inflammatory), and which other effects contribute
to its mode of action (e.g., sedation, tolerance)
(Oertel and Lötsch 2013; Okkerse et al. 2017;
Olesen et al. 2012; Staahl et al. 2009a). This can
be done in early clinical trials with healthy volun-
teers, which is not only cost-reducing but also
time saving. Other advantages of using human
evoked pain models are (1) stimulus intensity,
duration, and modality are controlled and do not
vary over time; (2) differentiated responses to
different standardized stimulus modalities; (3)
the response can be assessed quantitatively and
compared over time; (4) pain sensitivity can be
compared quantitatively between various normal/
affected/treated regions; (5) models of pathologi-
cal conditions can be studied and the effects of
drugs on such mechanisms quantified; and (6)
pain models can be easily performed in healthy
subjects, who are easier to recruit into clinical
studies (Arendt-Nielsen et al. 2007a).
Evoked pain is mostly short-lasting, with most
stimuli being applied exogenously and are
2 P. Siebenga et al.
generally focused on cutaneous nociceptor activa-
tion. Arguably, evoked pain models are limited in
intensity due to ethical constraints related to the
risk of tissue damage. In contrast to natural occur-
ring pain which is mostly caused by endogenous
factors, longer lasting and influenced by complex
emotions (Moore et al. 2013). Since clinical pain
is a complex sensation involving psychological,
physiological, and cognitive factors, no single
pain model is able to replicate all aspects of clin-
ical pain (Okkerse et al. 2017).
Several methods exist for evoking pain in
humans, such as mechanical, thermal, electrical,
and chemical stimulation. A stimulus can be either
phasic or tonic. Stimuli can be applied to different
tissue types for instance skin, muscles, or viscera
(Arendt-Nielsen et al. 2007a). This chapter
focuses on the different pain models that are
used to induce evoked pain in humans and the
means to assess the evoked pain. Human evoked
pain models are divided into the energy domain (i.
e., mechanical, thermal, electrical, and chemical
induction) and are further subdivided into area of
stimulation (i.e., skin, muscle, and viscera) that is
stimulated.
Pain Assessment Techniques
An evoked pain model consists of two elements; a
stimulus needs to be applied to evoke pain and the
related pain response needs to be measured
(Gracely 2013). Possible assessment techniques
for evoked pain responses can be divided into
several categories: psychophysical, electrophysi-
ological, and imaging.
Psychophysical Methods
Psychophysical methods aim to describe the rela-
tionship between physical stimuli (section “Pain
Stimulation Techniques”) and corresponding sub-
jective responses in a quantitative manner. These
methods are widely used to study stimulus pro-
cessing in various research fields, including pain
processing. The methods to quantify the relation-
ship between stimulus and response can be




Unidimensional questionnaires such as the
Numeric Rating Scale (NRS), the Verbal Rating
Scale (VRS), or the Visual Analogue Scale (VAS)
provide a single subjective measure to the inten-
sity of a stimulus. More quantitative unidimen-
sional measures are thresholds: the intensity
where a stimulus is first perceived as painful
(pain detection threshold), and the intensity
where the stimulus is no longer tolerable (pain
tolerance threshold).
Procedure and Evaluation
The NRS consists of a horizontal line with evenly
spaced perpendicular lines. The patient or subject
is asked to rate his or her pain from 0 to 10 (11
point scale) or from 0 to 100 (101 point scale)
where 0 equals “no pain” and 10 or 100 equals
“worst possible pain.” The VRS consists of a list
of descriptive terms to express the different levels
of pain. It at least should include the extremes, in
this case “no pain” and “worst possible pain.”
Additional terms usually used are “very mild
pain,” “mild pain,” “moderate pain,” “severe
pain,” and “very severe pain.” The VAS is a hor-
izontal line consisting of the two extremes and
subjects are asked to indicate on the horizontal
line indicating the perceived intensity.
For the determination of pain thresholds, the
stimulus intensity increases until a certain pain
threshold is reached (Gracely 2013). The pain
detection threshold (PDT) is reached when a
change in sensation from nonpainful to painful is
felt by the subject. The pain tolerance threshold
(PTT) is the stimulus intensity at which the pain is
no longer tolerable. Depending on the method
used, the stimulus is ceased before or when
reaching the pain tolerance threshold.
Several stimulus modalities (such as thermal,
mechanical, or electrical) can be used to quantify
pain perception and to assess sensory function
(Arendt-Nielsen and Yarnitsky 2009). These can
then also be used as an indicator of the current
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state of the pain system. For example, it can be
used to detect hyperalgesia, which is a condition
in which an enhanced pain response to noxious
stimuli is observed. Hyperalgesia is indicated by a
decrease in the pain thresholds and an increase in
pain to supra-threshold stimuli.
Critical Assessment of the Method
The main disadvantage of NRS, VRS, and VAS
scales is that they measure a single qualitative
aspect of pain, namely, intensity or unpleasant-
ness, while pain consists of more qualities (section
“Multidimensional Measures”). Moreover, even
though these (subjective) unidimensional scales
can be used as a coarse measure of the level of
pain a subject experiences, they cannot be used to
distinguish individual contributions of nocicep-
tive and pain-related mechanisms.
Modification of the Method
To obtain a more detailed description of pain
perception and qualities, multidimensional ques-
tionnaires can be used (section “Multidimensional
Measures”).
More advanced psychophysical procedures are
being developed to relate stimulus properties (e.
g., pulse width, number of pulses, and inter-pulse
interval) and perceptions to nociceptive processes
(Doll et al. 2016; Yang et al. 2015). Also, com-
bining unidimensional measures with neurophys-




Unidimensional questionnaires are often found to
be limited in their capabilities in describing pain
perceptions. Therefore, multidimensional mea-
sures provide means to describe perception using
multiple sensory and affective qualities of pain.
Procedure
In contrast to the unidimensional measures, sub-
jects are asked to fill in several answers to various
questions, or have to choose from a large range of
adjectives to describe their pain perception. One
of the most widely used multidimensional tool is
the McGill Pain Questionnaire (Melzack 1975).
This questionnaire not only measures the pain
intensity but also measures the sensory and affec-
tive qualities of pain. The McGill Pain Question-
naire has been used in a large number of studies
and has been translated and validated in multiple
languages (Melzack 2005; Melzack and Katz
2013).
Critical Assessment of the Method
Multidimensional questionnaires often take more
time to complete than simpler unidimensional
questionnaires. Particularly in a clinical setting,
multidimensional questionnaires either need to be
compressed (such as the short-form McGill Pain
Questionnaire) or replaced by unidimensional
questionnaires. Additionally, in the experimental
setting of evoked pain models not all components
of a questionnaire may be applicable, e.g., items
related to affective aspects of pain sensation.
Modification of the Method
Numerous pain questionnaires exist that measure
different qualities of neuropathic and non-neuro-
pathic pain. These include the Pain Quality
Assessment Scale (PQAS), Leeds Assessment of
Neuropathic Symptoms and Signs (LANSS), and
PainDETECT. Moreover, questionnaires
targeting specific patients groups exist as well;
the Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC) and Knee Soci-
ety Score (KSS) assign pain, stiffness, and func-




Electrophysiological readouts include evoked
potentials via electroencephalography (EEG).
Imaging readouts include functional magnetic res-
onance imaging (fMRI) and positron emission
tomography (PET). Electrophysiological and
imaging readouts provide a more objective mea-
surement of pain. However, they have a larger
variation in outcome measurements, are more
expensive, and are technically more difficult to
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perform in a large group of subjects (Arendt-Niel-
sen et al. 2007a; Kakigi et al. 2005; Wager et al.
2013).
Functional Magnetic Resonance Imaging
Purpose and Rationale
Neuroimaging has identified several cortical
regions in the brain that are typically active
when a painful stimulus is applied to the body.
With fMRI these pain responses in the brain can
be observed. Structures that are active during pain
perception are the primary and secondary somato-
sensory, the cingulate, and the insular cortices
which together are called the pain matrix (Ingvar
1999; Peyron et al. 2000; Porro 2003; Rainville
2002; Tracey andMantyh 2007). Activation of the
pain matrix due to nociceptive stimuli is the func-
tional imaging analogue of conscious pain percep-
tion. Measuring the activities in the pain matrix
during a painful stimulus can be used as an objec-
tive measure for pain perception (Borsook et al.
2010).
Procedure and Evaluation
A subject is given a painful stimulus while being
scanned in the MRI. fMRI measures brain activity
by detecting changes in blood flow (hemody-
namic response) associated with neuronal activa-
tion (Huettel et al. 2014). It uses the relative
abundance of deoxyhemoglobin in blood that
changes the proton signal from water molecules
surrounding a blood vessel, producing blood oxy-
genation level-dependent contrasts (BOLD)
(Ogawa et al. 1990). Via the BOLD signal an
indirect index of neural activity is provided. Sev-
eral fMRI methods are used in pain research,
which reveal the neural correlation of pain per-
ception and modulation by characterizing the
brain response to evoked stimuli (e.g., pain, allo-
dynia), task-driven responses, or drugs (phMRI)
(Borsook et al. 2010).
Critical Assessment of the Method
This noninvasive method of measuring pain can
provide a measure of cerebral perfusion that cor-
relates with an acute painful stimulus in healthy
volunteers. Detecting chronic pain is more
complex due to confounding factors like disease
and treatment. Brain systems like emotion, mem-
ory, and motivation are also active during mea-
surement in these patients (Borsook et al. 2010).
These systems can also be triggered by placebo
analgesia, which adds to the complexity (Morton
et al. 2016). Additionally, the resolution of fMRI
is inferior compared to the EEG, which means that
it is not suitable to investigate the primary neuro-
nal activity directly related to the pain stimulus
and less suitable to investigate the deeper struc-
tures of the brain (e.g., brainstem and thalamus)
(Olesen et al. 2012).
Modifications of the Method
When including fMRI in a study, a distinction can
be made in the type of pain model that will be used
during the study. Mechanical (Baron et al. 1999),
thermal (Lapotka et al. 2017; Shukla et al. 2011),
electrical (Kocyigit et al. 2012), and chemical
(Baron et al. 1999) induced pain models can be
used during an fMRI scan, with the exception of
models that entail the use of water and metal.
Modifications can be made in the type of MRI,





EEG is a noninvasive technique which records
(spontaneous) synchronized postsynaptic neuro-
nal activity of the human cortex. In contrast to
brain imaging techniques, EEG has a high tempo-
ral resolution. This high resolution makes EEG an
effective method of observing (rapid) changes in
brain activity. Additionally, EEG is a suitable
method for recording evoked potentials (EP) to
painful stimuli (e.g., thermal, mechanical, or elec-
trical) and may provide important information on
(central) pain processing (Mouraux and Iannetti
2008).
Procedure and Evaluation
To record EEG, several electrodes are placed on
the scalp, either using individual Ag/AgCl elec-
trodes or specialized caps. The impedance should
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be similar among all electrodes and is advised to
be held under 50 kΩ. Quantifying resting state
EEG can be done by means of spectral analysis.
Due to its nonstationary behavior, recorded data is
divided in short epochs ranging between 2 s and
10 s (Jobert et al. 2013). Each epoch is then
transformed into the frequency domain and after
removing or correcting epochs affected by arti-
facts (e.g., ocular or muscular activity) averaged.
The frequency range is then subdivided into bands
(i.e., delta, theta, alpha, beta, and gamma) and
then integrated over frequency bands to obtain
the total power per frequency band.
EPs are monophasic deflections of spontane-
ous EEG and are time and phase locked on the
onset of the stimuli (Mouraux and Iannetti 2008).
These waveforms are typically characterized by
their polarity, latency, amplitude, and position on
the scalp. As the signal-to-noise ratio (SNR) is
relatively low when recording EPs, repeatedly
stimulating and recording cortical responses is
required. This allows improving the SNR by
means of averaging and allows the characteriza-
tion of the evoked response in terms of the ampli-
tudes and latencies. The data collected generally
includes the peaks and latencies of the N1, N2, P2,
and P3, or the top-top amplitude between N2 and
P2 (Treede et al. 2003). Moreover, the reaction
time after the presentation can also be recorded.
The N1 is most prominent at the contralateral
temporal side (i.e., T3 or T4) referenced to the
frontal Fz. The N2 and P2 are most prominently
visible at the vertex Cz referenced to the (linked)
earlobes A1 and A2. The P3, which is not thought
to be nociceptive specific, has a relatively long
latency and is best observed at Pz referenced to the
earlobes.
Critical Assessment of the Method
It is important to know that EEG recordings will
be contaminated with artifacts. Common sources
of artifacts are ocular movements and blinks, mus-
cle contraction, and cardiac activity. Each of these
artifacts have their own characteristics in both
time domain and frequency domain and must be
dealt with prior to analyzing EEG. Possibilities for
dealing with these artifacts are either excluding
parts of the recording for analysis or correcting for
them (e.g., by using regression techniques, filter-
ing, or blind source separation techniques).
EPs have been shown to be sensitive to various
changes in pain pathways. EPs are sensitive to
changes induced by analgesics (Schaffler et al.
2017). It must be taken into account, however,
that the amplitudes of the EPs are dependent on
the attention of the subject; reduced attention
results in significantly lower peak amplitudes.
Moreover, the across trial variability is relatively
high making comparisons between groups and
trials complicating.
Modification of the Method
When several electrodes are recorded during a
resting state EEG, multichannel topography
allows observing the activity recorded at several
locations. Time-dependent changes in power
spectra can therefore also be visualized. Even
though EEG has a relatively low spatial distribu-
tion in contrast to techniques such as fMRI, source
localization techniques are used to find brain
sources of the recorded potentials (Grech et al.
2008). However, high-density electrode place-
ment is required for more reliable source localiza-
tion (Song et al. 2015).
As a result of averaging EPs, non-phase-locked
information is lost. Time-frequency analysis of
epochs does provide the means to study non-
phase-locked information (Hu et al. 2015;
Mouraux and Iannetti 2008).
Nociceptive Spinal Flexion Reflex
Purpose and Rationale
The nociceptive spinal flexion reflex (NFR), also
called the RIII reflex, is a physiological, polysyn-
aptic reflex allowing for painful stimuli to activate
an appropriate withdrawal response (Skljarevski
and Ramadan 2002). It is one of the available tools
for objective quantification of spinal nociception
in humans. The NFR reflex can be elicited in all
four limbs. Here, the most standard procedure,
with stimulation of the lower limb (sural nerve),
is described.
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Procedure and Evaluation
Electrical constant current stimulation is delivered
to the retromalleolar pathway of the sural nerve.
Each stimulus consists of five pulses of 1 ms
duration, separated by 4 ms, resulting in a total
duration of 21 ms. Electromyographic responses
are recorded from the ipsilateral biceps femoris
(short head) via surface electrodes placed 4–5 cm
apart over the muscle belly. The RIII reflex is
identified as a polyphasic muscle response
appearing with an onset latency between 90 ms
and 130 ms after stimulation (Willer 1977). Fol-
lowing stimulation of the sural nerve, three
responses are sequentially recorded: the tactile
reflex (also known as RII), the nociceptive flexion
reflex (RIII), and an involuntary movement signal
(Skljarevski and Ramadan 2002). For quantifica-
tion of the RIII reflex response, the reflex area is
obtained by integrating the rectified signal within
a 50 ms analysis window starting between 90 ms
and 120 ms after stimulation. Stimulus–response
curves are recorded by increasing stimulation
intensity in 0.5 mA steps starting from 0.5 mA.
Participants can rate the pain intensity of each
stimulus using an NRS or VAS. The pain thresh-
old is determined as the stimulus intensity that
first evokes a painful sensation (defined as an
NRS rating  1 or VAS > 0). The RIII threshold
is defined as the stimulus intensity that first evokes
a reflex response exceeding a raw area of
100 μV  ms (Ruscheweyh et al. 2015).
Critical Assessment of the Method
Reduction of the NFR by a pharmaceutical com-
pound does not necessarily imply reduction of
ascending nociception, but may also indicate
modulation of other components that play a role
in the RIII reflex, such as deep dorsal horn inter-
neurons (Schouenborg et al. 1995) or motor neu-
rons (Ruscheweyh et al. 2015).
Modifications of the Method
NFR is affected by demographic factors. It is
indicated that female subjects and children have
lower NFR thresholds (Page and France 1997;
Sandrini et al. 1989). Other factors affecting the
outcome include cardiac cycle, baroreceptors,
stimulation site, and even diurnal rhythm
(Skljarevski and Ramadan 2002). All should be
addressed before the start of the trial.
Conditioned Pain Modulation
Purpose and Rationale
Conditioned pain modulation (CPM) (also known
as descending noxious inhibitory control (DNIC)
for animal studies or heterotopic noxious counter-
stimulation) is a paradigm that uses a conditioning
stimulus to influence a test stimulus and can be
used to assess the endogenous analgesic capacity
of both healthy subjects and patients (Nir and
Yarnitsky 2015). The assessment of CPM pro-
vides an indication of the balance between
descending facilitation and inhibition. It is
hypothesized that malfunction of pain modulation
network may be the cause, rather than the effect,
of chronic pain development (Yarnitsky et al.
2010).
The endogenous network is mediated via
descending serotonergic, noradrenergic, and
dopaminergic pathways, with the conditioning
stimulus activating decreasing the activity of on-
cells in the rostral ventromedial medulla (RVM)
(Hernández et al. 1994).
Procedure and Evaluation
CPM is assessed by using a conditioning stimulus
which is generally a tonic nociceptive stimulus;
however, nonpainful conditioning stimuli have
also been reported (Bouhassira et al. 1998;
Lautenbacher et al. 2002). Various methods can
be used as the conditioning stimulus. The method
most commonly used is the cold pressor test (Pud
et al. 2009). However, other stimuli have also
been reported including hot water, ischemic
pain, heat, chemically induced pain, electrical
induced pain, and physically induced muscle
pain (Popescu et al. 2010).
Various methods are used as the test stimulus
including nociceptive flexion reflex, electrical,
heat, and pressure stimulation, among others.
CPM is considered to be a systemic experience,
and as such, heterotopic stimulation is used for the
assessment of CPM. CPM is assessed by compar-
ing the endpoint from the test stimulus before and
after administration of the conditioning stimulus.
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The duration of effect from the conditioned stim-
uli may be assessed in parallel or soon after
administration of the conditioning stimulation;
however, the duration of effect is paradigm-
dependent with reports of CPM effects lasting
5 min, 30 min, and up to 60 min after application
of the conditioning stimulus (Fujii et al. 2006;
Graven-Nielsen et al. 1998; Tuveson et al. 2006).
Critical Assessment of the Method
CPM paradigms are reported to have both reason-
able to high intra- and inter-individual variability
especially due to the endpoint being derived from
subjective pain reports (Nir and Yarnitsky 2015).
Furthermore, divergent terminology used in the
literature for the same phenomena complicate
comparisons. Factors affecting CPM are use of
medication, psychological state of subjects (anxi-
ety, depression, emotional status, and attention
span), and even ethnic origin (Goubert et al.
2015).
Modifications of the Method
As highlighted above and as with other pain
models, there are numerous ways to assess CPM
including different methods for the conditioning
and test stimulus including using different appli-
cation area. Furthermore, the endpoints vary con-
siderably between research groups, with some
groups assessing change in the test stimuli end-
point before and after the conditioning stimuli
while others reporting changes in the endpoint
during administration of the conditioning stimu-
lus (Doll et al. 2014).
Pain Stimulation Techniques
Mechanical Stimulation
Human evoked pain models date back to the late
nineteenth century, in which mechanical pressure
was used to induce pain (Hardy et al. 1940). Over
time, mechanical stimulation techniques became
more accurate and are used to stimulate the skin,
muscle, or viscera. The skin is the most used
organ, because of its practical implementation.
However, muscles can also be targeted both
endogenous (post-exercise or ischemic) or exog-
enous (saline injection). Balloon distention in the
viscera can be used to investigate new analgesic
compounds in healthy volunteers but also as a
diagnostic tool in patients (e.g., gut disorders).
Mechanical stimulation can be divided into
touch/pinprick, pressure, or pinching methods.
This chapter focuses on the different techniques
related to mechanical stimulation on the skin,
muscles, and viscera using touch/pinprick, pres-




Mechanical stimulation via touch can be done
with a cotton swab or a brushstroke (light mechan-
ical stimulation) or pinprick. Light mechanical
stimulation will not induce pain, but can be used
to assess allodynia (lowered activation threshold
for a nonpainful stimuli) by other pain stimuli.
A common method of applying pinprick stim-
ulation is the use of von Frey filaments. These
filaments are used to quantify touch as well as
the PDTand the PTT. In animal and patient exper-
iments, it is mostly used to determine functional
recovery of Aδ- or Aβ-fibers. In human pain
models, it is also used to determine hyperalgesia
effects (e.g., in the capsaicin/UV-B model).
Procedure and Evaluation
Von Frey filaments are calibrated filaments, orig-
inally made of human or animal hair, and later
with acrylic or synthetic fibers or optical glass
fibers. The filaments bend at a certain designated
force (Fruhstorfer et al. 2001). The applied force is
dependent on the stiffness, which is in turn depen-
dent on the diameter of each filament. During
stimulation, the filament is placed perpendicular
to the skin and pressed down with a constant
increase in force until it bends for 1 s. Subse-
quently, the filament is removed with a constant
decrease in force and the subject is given some
time to evaluate the stimulation.
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Critical Assessment of the Method
The von Frey test is characterized by its simplic-
ity, thereby showing advantages in clinical set-
tings for rough quantification of functional nerve
regeneration. In addition, it can be used to classify
responders in the evaluation of hyperalgesia.
Although the von Frey method is still com-
monly used to evaluate peripheral nerve function
in patients, it has several disadvantages as a
human pain model. Pinprick stimulation always
coactivates non-nociceptive Aβ-fibers. This may
contaminate the signal and influence the results
affecting the specificity. Additionally, intra- and
inter-observer variability of this method is high.
The skill of the observer will have an important
impact on the results. Furthermore, each filament
is produced for one constant standardized level of
pressure, which means that many filaments are
needed to determine sensory or pain thresholds
with a high precision. Environmental changes
may affect the calibration of the filaments. Lastly,
it is difficult to combine von Frey stimulation with
quantification methods that require time-locked
responses, such as evoked potentials or time-fre-
quency analyses in EEG.
Modifications of the Method
Von Frey filaments are inherently limited for
method modification, because each filament is
calibrated for one designated force application.
Depending on the calibrated force, the filaments
activate mainly Aβ-fibers (0.5–128 mN) or Aδ-
fibers (128–512 mN) (Curatolo et al. 2000). Both
conventional as electronic pinprick paradigms
have been described (Möller et al. 1998). To elim-
inate the intra- and inter-observer variation one
can consider electronic pinprick devices.
Impactometers/Pinch Interdigital Web/Joint
Purpose and Rationale
Pressure algometers are usually applied to the
muscle or bone, but other sites including the
interdigital web, skinflap, earlobe, or a finger or
toe joint can be used as an area of investigation
(Brennum et al. 1989; Curatolo et al. 1997; Staahl
et al. 2006). Handheld or computer controlled
pressure algometers are clinically similar to pal-
pation (Olesen et al. 2012). For methods using a
pinch methodology, the pain is due to a combina-
tion of mechanical stimulation and local ischemia,
while when pressure is applied to muscle the pain
is related to muscle strain (Olesen et al. 2012).
Procedure and Evaluation
A pressure algometer is applied to the area of
interest. In a controlled manner, the pressure
increases at a constant rate until a psychophysical
endpoint of interest is attained. Many commercial
handheld pressure algometers provide user feed-
back to ensure pressure is applied at a constant
rate. For repeated applications, the pressure
algometer should be applied to the same area to
ensure intra-individual variability is minimized as
variation in location can lead to different thresh-
olds. PDT and PTTare the usual primary outcome
measures.
Critical Assessment of the Method
For handheld pressure algometers, control of the
rate of onset, muscle contraction, and examiner
expectations are the primary limitations (Woolf
and Max 2001). Differences in the size and
shape of the probe limit comparisons between
research groups.
Modifications of the Method
The model can be used in combination with other
methods that induce hyperalgesia or sensitization.
Stimulus-response curves can be compared with
nonsensitized locations.
Rather than using a punctate pressure
algometer, cuff algometry can be used with the
advantage that the model is generally computer-
controlled thereby controlling the rate of applica-
tion of the pressure pain (Polianskis et al. 2001).
Pain induced by cuff algometry is primarily
related to muscle pain with minimal contribution
from skin nociceptors.




Delayed onset muscle soreness (DOMS) is
believed to be mediated by a combination of lactic
acid, muscle spasm, connective tissue damage,
muscle damage, inflammation, and endogenous
substances (e.g., bradykinin and prostaglandines)
(Nie et al. 2006). This pain model is thought to
mimic clinical pain by inducing central sensitiza-
tion while having no spontaneous pain at rest
compared with exogenous induced pain models
(Olesen et al. 2012). Central sensitization is an
increase in general excitability of the dorsal horn
neurons which can be caused by nerve injury
(Laird and Bennett 1993). Secondary hyper-
algesia is thought of as a transient state of central
sensitization (Torebjörk et al. 1992).
Procedure and Evaluation
Subjects perform an eccentric exercise that they
are unaccustomed to with insufficient rest periods.
Peak allodynia/hyperalgesia occurs 24–48 h post-
exercise. The affected muscles are assessed with a
VAS to evaluate pain intensity and pressure
algometry to evaluate allodynia/hyperalgesia.
Critical Assessment of the Method
The method is somewhat nonspecific, with an
inflammatory component but these may be site
specific (Staahl and Drewes 2004).
Modifications of the Method
The method can be modified by using various
locations/muscle groups with development of
hyperalgesia dependent on the size of the muscle
(Svenson and Arendt-Nielsen 1995).
Ischemic Tourniquet
Purpose and Rationale
The tourniquet model is a tonic pain model with
nociceptive contributions from the muscle, skin,
and periosteum (the vascular connective tissue
enveloping the bones). Clinically, tourniquets are
used to perform intravenous regional anesthesia
or to provide a bloodless operating field. The
tourniquet leads to metabolic changes, primarily
acidosis, and compression which leads to the
release of prostaglandins. Neuropathic pain
induced by nerve compression may also contrib-
ute to the pain felt (Kumar et al. 2016). The
method can also be used as a conditioning stimuli
for the CPM paradigm (section “Conditioned Pain
Modulation”).
The pain is thought to be mediated by the
unmyelinated, slow conducting C-fibers that are
usually inhibited by the Aδ-fibers (Kumar et al.
2016). The Aδ-fibers are blocked by mechanical
compression after about 30 min, while the C-
fibers continue to function (Casale et al. 1992).
Tourniquet compression leads to release of pros-
taglandins by the injured cells (Kumar et al.
2016). These prostaglandins increase pain percep-
tion by sensitizing and exciting pain receptors.
Also, limb ischemia causes central sensitization
(Kumar et al. 2016).
Procedure and Evaluation
A pneumatic tourniquet is applied to an extremity,
generally the thigh, following exsanguination of
the leg. The cuff is inflated above the systolic
blood pressure with ranges of 100–600 mmHg
above the systolic pressure having been reported
(Smith et al. 1966).
Critical Assessment of the Method
For healthy subjects, the tourniquet can be left for
up to 2 h; however, pain is nonspecific with pain
being felt under the tourniquet and/or in the lower
limb. The method can also lead to temporary
hypoesthesia and lower limb paralysis. Following
reperfusion, the subject may experience hyper-
algesia/allodynia and muscle cramps in the
affected limb.
Modifications of the Method
The method can also be used with combination
with voluntary muscle contractions or exsangui-
nation of the leg by gravity or esmarch bandage
(Hagenouw et al. 1986; Olesen et al. 2012). The
width and type of tourniquet and the maximum
inflation pressure can be used to modify the
method.
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Hypertonic Saline Injection
Purpose and Rationale
Intramuscular injection of hypertonic sodium
chloride (4–6%) results in a tonic, deep, diffuse
pain. The pain usually lasts for several minutes
following infection and leads to both local and
referred pain. The pain is primarily mediated via
direct excitation of C-fibers than caused by saline-
induced tissue injury (Schulte et al. 2006;
Svendsen et al. 2005). The procedure can also be
used to induce local, cutaneous hypoesthesia
(Graven-Nielsen et al. 1997).
Procedure and Evaluation
A bolus saline solution is injected intramuscularly
using computer-controlled infusion pump. Earlier
models used manual bolus injections (Graven-
Nielsen and Mense 2001). Pain intensity is mea-
sured by using a VAS with peak pain or area under
the curve (AUC) being the primary outcome mea-
sures. Referred pain patterns and changes in the
pressure pain thresholds of the local and referred
pain areas can also be assessed (Ge et al. 2006).
Critical Assessment of the Method
A limitation of the model is that hypertonic injec-
tion may elicit excitation from both non-nocicep-
tive and nociceptive nerve fibers (Korotkov et al.
2002).
Modifications of the Method
Potassium chloride is occasionally used instead of
sodium chloride. Various sites can be used for
injection with the most common being the
musculus trapezius and the musculus tibialis ante-





Induction of pain in viscera is difficult to perform
due to the location of the organs associated with
visceral pain as pain originates from the internal
thoracic, pelvic, or abdominal organs (Johnson
and Greenwood-van Meerveld 2016). Evoked
pain models assessing mechanical visceral pain
are generally limited to different accessible areas
of the gastrointestinal (GI) tract, the urinary tract
(Maggi 1990), and the uterine cervix (Drewes et
al. 2003a).
Procedure and Evaluation
Mechanical stimulation of the viscera is generally
performed using a balloon placed in the GI tract
with the preferred locations being the esophagus
or rectum. The most common method used is the
barostat method whereby changes in air volume
within a balloon while maintaining constant pres-
sure are measured (Drewes et al. 2002). Generally,
the balloon/bag is inflated until moderate pain is
reported (up to approximately 7 on a VAS) and the
corresponding balloon volume is reported (Staahl
et al. 2006).
Critical Assessment of the Method
One of the main limitations of organ distention is
the distortion of the balloon. However, calculation
of strain by impedance planimetry or calculation
of balloon radius may overcome these limitations
(Drewes et al. 2003a; Staahl et al. 2006). Assess-
ment of visceral pain is difficult due to the diffuse,
referred, vague, and deep nature of the pain asso-
ciated. Furthermore, autonomic reactions and the
risk of perforation may limit the use of visceral
pain models (Ness and Gebhart 1990).
Modifications of the Method
Perfusion of the GI tract with chemical substances
(e.g., acid or capsaicin) can be used to sensitize
the organs and nervous system and generally
mimics the clinical situation where the organs
are hypersensitive (Johnson and Greenwood-van
Meerveld 2016).
Thermal Stimulation
Thermal stimuli can be used to induce pain. These
can be roughly subdivided in cold and heat stim-
uli. Cold stimulation can be induced by emerging
a body part in a cold water bath (cold pressor test),
by using a cooling thermode, by inducing a
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freezing lesion, or by applying ice directly to the
skin. Heat pain tasks are among the most widely
used pain models in human volunteers to investi-
gate nociception, due to the relative ease of appli-
cation and robustness. Nociceptive nerve fibers
are activated by changes in temperature detected
by a range of thermal receptors, of which Tran-
sient Receptor Potential ion channel subfamily
vanilloid (TRPV) is most responsible. When a
sharp increase in temperature (>43) is detected,
Aδ-fibers are activated, whereas C-fibers are acti-
vated by slower or more dull temperature changes.
Different clinical pain states can lead to sensitiza-
tion to heat pain stimuli and consequently lower






The cold pressor test can be used to investigate
nociception, but also cardiovascular responses
(sympathetic functions) and can be used as to
induce CPM. The cold sensation and pain induced
by this method is mediated by activity of Aδ-
fibers (cold sensation) and C-fibers (cold pain)
(Olesen et al. 2012).
Procedure and Evaluation
One of the methods of induction of cold pressor
pain is based on methods previously described by
Eckhardt et al. and Jones et al. (Eckhardt et al.
1998; Jones et al. 1988). Here, subjects place their
nondominant hand into a warm water bath for
2 min. At 1 min 45 s, a blood pressure cuff on
the upper-arm is inflated to 20 mmHg below rest-
ing diastolic pressure. At 2 min, the subject moves
their hand from the warm water bath, directly
placing their hand into a cold water bath. The
baths are two thermostat-controlled, circulating
water baths set at 35.0  0.5 C and
1.0  0.5 C, respectively. The subject rates
their pain intensity using a rating scale (e.g.,
VAS or NRS). When pain tolerance is reached,
or when a time limit is reached, subjects are
instructed to remove their arm from the water, at
which point the blood pressure cuff is deflated.
Typically, PTT expressed in seconds after immer-
sion in the cold water is recorded as primary
outcome measure.
Critical Assessment of the Method
Many different methodologies have been
described which negatively influences the extent
to which different studies can be compared. Small
variations in water temperature can result in sig-
nificant changes in pain intensity and tolerance
times (Mitchell et al. 2004). Therefore, it is impor-
tant to use water baths that are able to circulate
that water to prevent warming of the water around
the hand.
Modification of the Method
Different temperature settings of the water baths
can be used and different body parts can be
immersed in the baths. Instead of a cold water
bath, also a cool gel substance has been reported
to induce pain which makes it suitable for fMRI
testing (Lapotka et al. 2017). Also a blood pres-
sure cuff can be used to prevent compensatory
blood flow to the hand.
Cooling Thermode
Procedure and Evaluation
The cold pressor test (section “Cold Pressor”) is
the most commonly used method to induce cold
pain. However, a cooling thermode can also be
used to induce cold pain. A contact thermode is
attached to a part of the human body. The method
consists of administering a temperature with an
intensity that gradually decreases at a constant
rate, usually 1 C per second. The subject halts
the stimulus when the cold pain threshold is
reached or when a set lower cut off temperature
is reached. Most studies using this methodology
only report the cold pain detection threshold; the
temperature at which the sensation has “just
become painful.”
12 P. Siebenga et al.
Critical Assessment of the Method
For none of these compounds this methodology
provided evidence for analgesic efficacy, while
other pain induction methods were able to provide
this evidence (Staahl et al. 2009a, b). The added
value of this methodology in clinical pharmacol-
ogy studies is limited.
Modification of the Method
Several adjustments can bemade to this paradigm.
The temperature at which the test starts, the rate at
which the temperature decreases, and the temper-
ature at which the test ends can be modified. Cold
hyperalgesia can be induced by applying menthol
to the skin prior to testing (Andersen et al. 2015).
A mean threshold of multiple measurements can
be taken to minimize subject variability.
Thermal Grill
Purpose and Rationale
The thermal grill is based on the phenomenon in
which simultaneous application of innocuous
cutaneous warm and cold stimuli can induce a
sensation of burning pain, the so-called “thermal
grill illusion.” The illusion is thought to be caused
by the central integration of ascending pain and
temperature sensory channels, where the inhibi-
tion that is usually exerted by the cold afferents on
the nociceptive system is reduced (Bouhassira et
al. 2005; Craig and Bushnell 1994).
Procedure and Evaluation
The thermal grill consists of a number of juxta-
posed bars of cold and warm nonpainful temper-
atures (e.g., 18 C and 42 C) on which the subject
places a body part for a certain period of time.
Possible outcome measures, during and after the
test, can be cold and hot sensation, pain intensity,
and sensation of unpleasantness.
Critical Assessment of the Method
Studies in which the thermal grill has been used
applied a range of combinations of warm and cold
stimuli to assess relationships between painful
and nonpainful sensations (Adam et al. 2014;
Kern et al. 2008; Okkerse et al. 2017). The occur-
rence of paradoxical pain elicited by the thermal
grill illusion can be variable. A study by
Bouhassira and colleagues reported a large sub-
population of subjects who only reported para-
doxical pain when large cold-warm differentials
were applied (Bouhassira et al. 2005). Due to the
apparent necessity to tailor this method to each
individual subject, it is difficult to standardize this
method.
Modification of the Method
For the induction of the thermal grill illusion,
different temperature combinations of the cold
and warm bars can be used. Also a different num-
ber and width of the bars and a different distance
between the bars can be used.
Skin Freezing
Purpose and Rationale
Skin freezing is an induction method of hyper-
algesia. Hyperalgesia can be experimentally
induced with chemical and electrical stimulation
or by injuring tissue using UVB or freeze lesions
(Kilo et al. 1994; Lötsch and Angst 2003).
Procedure and Evaluation
A copper cylinder is cooled to28 C and placed
to a part of the skin for a brief period of time. For
better thermal contact, a filter paper soaked with
saline can be placed between the skin and the
copper cylinder. This freezing induces cutaneous
inflammation and hyperalgesia. Approximately
24 h after induction sensory testing can be
performed.
After induction of the freeze lesion, pain and
sensation testing can be performed via mechanical
stimulation with stroking brushes (subjects have
to indicate if a stroke with a certain load is pain-
ful), von Frey filaments (with increasing strength,
subject have to indicate when the punctuation
becomes painful) and blunt pressure using a pres-
sure algometer (threshold in N/cm2), or electrical
stimulation using a constant current device
(thresholds in mA).
Critical Assessment of the Method
There are only a handful of studies reporting using
freeze lesions. An advantage of this method is the
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extent to which this methodology can be standard-
ized. The temperature, pressure, and exposure
time for induction of the lesion can be controlled.
Furthermore, the lesion provides stable test con-
ditions 1 day after induction. The lesion ceases
over a period of days (Lötsch and Angst 2003).
The freeze lesion may cause hyperpigmentation,
which can be visible for several months (Kilo et
al. 1994).
Modification of the Method
The location, temperature, pressure, and exposure
time for induction of the lesion can be varied.
Furthermore, the time window between induction




Heat pain thresholds can be determined by apply-
ing a peltier element to the skin, where the
increase in temperature activates nociceptors via
TRPV and TRPM channels (Caterina et al. 1997;
Li 2017).
Procedure and Evaluation
A contact heat thermode probe, typically with a
surface of 9.0–12.5 cm2, is placed on the skin at a
standardized nonpainful baseline temperature
between 30 C and 39 C. Temperature is subse-
quently increased in a tonic or phasic fashion at a
predetermined rate up to a temperature of
50–52 C. After a subject has indicated its pain
detection or tolerance threshold, the probe is rap-
idly cooled to the baseline temperature. To reduce
variability, the test can be repeated consecutively
three times, and the average of these measure-
ments is considered the pain threshold (Bishop et
al. 2009). Outcome measures consist of pain
thresholds as well as subjective pain scores
(NRS, VAS).
Critical Assessment of the Method
Heat pain thresholds are considered to be robust
and reproducible endpoints, due to their clear
physiological relationship with nociceptor
activation thresholds. This method is widely
used and contact heat thermodes are commercially
available. Limitations to using a contact heating
thermode is the relatively slow heating and
cooling rate of the thermode, and the fact that
the thermode touches the skin compared to, for
example, laser, making it less suitable for investi-
gating temporal summation or specific activation
of Aδ-fibers.
Modifications of the Method
In addition to investigating pain sensation in
healthy skin, this method is often used to quantify
sensitization, by comparing pain sensation of nor-
mal skin to an area of sensitized (UVB, capsaicin,
menthol, cinnamaldehyde) skin (Roberts et al.
2011; Schaffler et al. 2017). The contact heat
thermode can be used in conjunction with an
EEG or fMRI modality, together known as
CHEPS (Contact Heat Evoked Potentials). (Rob-
erts et al. 2008, 2011).
UVB Erythema
Purpose and Rationale
Inflammation is the biological response to any
type of bodily injury and is recognized by
increased blood flow, elevated cellular metabo-
lism, vasodilatation and the release of soluble
mediators, and extravasation of fluids and cellular
influx. Many different neuro-active factors are
released during inflammation which stimulate
nociceptors itself or by lowering the depolariza-
tion threshold of afferent nerves. The UVB (or
“sunburn”) model is regarded as a model for
inflammatory pain and as such it is most sensitive
to the effects of NSAIDs (Bishop et al. 2009; van
Amerongen et al. 2016); in this model, hyper-
algesia is evoked by exposing an area of skin to
an individualized dose of UVB on the skin.
Procedure and Evaluation
Prior to the start of the study, the minimal ery-
thema dose (MED) for a subject is determined
(Sayre et al. 1981). Subsequently, a one-, two-,
or threefold multiple of this dose is applied to the
skin. Over the course of 2–96 h, a clearly discern-
ible dose-related area of erythema becomes
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apparent, where allodynia and hyperalgesia is
observed. Maximum hyperalgesia is reached at
24 h after irradiation. Typically, no background
pain is observed. UVB induced hyperalgesia or
allodynia can be quantified using a thermal (heat
or cold) or mechanical (stroking, pinprick, pres-
sure algometry) challenge. Pain thresholds or a
subjective pain score can be used as endpoints.
Mechanical allodynia to pinpricks or a pressure
algometer can be expressed as a PDT, when
ascending strengths of von Frey filaments are
used. Moreover, the area of allodynia is measured
using a fixed von Frey filament or brush.
Critical Assessment of the Method
The UVB model has been proven to be valuable
tool to induce hyperalgesia and allodynia associ-
ated with inflammatory pain. One caveat, how-
ever, is the risk of postinflammatory
hyperpigmentation (PIH) (Brenner et al. 2009).
PIH is a harmless condition in which areas of
skin become darker in color compared to the
surrounding skin. PIH can occur at any age and
any skin type; however, it is more common in
patients with darker skin (Fitzpatrick skin type
4–6) (Fitzpatrick 1988).
Modifications of the Method
In general, there are three degrees of freedom to
modify the UVB method: (1) the dose can be
altered between estimated 1 to 3 MED (Bauer et
al. 2015; Gustorff et al. 2004; Ing Lorenzini et al.
2012); (2) the location can be varied between leg,
arm, and back; and (3) the time between UVB
exposure and hyperalgesia assessment may vary
between 12 h and 36 h.
Heat Burn Model
Purpose and Rationale
A first-degree burn, comparable to a slight sun-
burn, resulting from a heat stimulus is used to
initiate a local inflammatory response which
results in reduced pain sensation thresholds
(Thalhammer and LaMotte 1982). Additionally,
the intense nociceptive excitation is thought to
induce central sensitization (Pedersen and Kehlet
1998; Woolf 1983), rendering the burn model a
model for both peripheral and central neuronal
sensitization.
Procedure and Evaluation
A superficial cutaneous burn is induced using a
thermode at a fixed temperature of 45–47 C, for a
period of 2–7 min, which is applied at a standard-
ized pressure on the skin. The leg is predomi-
nantly selected as the location, but the arm is
also used. The acceptable timeframe for detect-
able hyperalgesia and allodynia is typically up to
4 h after exposure to the heat stimulus. A distinc-
tion in sensitization can be made when investigat-
ing responses in the primary (exposed) area and
the secondary (adjacent, nonexposed) area.
Hyperalgesia resulting from the heat burn model
is most distinctly quantified using a thermal or
mechanical stimulus, due to locally reduced pain
sensation thresholds in the primary area (van
Amerongen et al. 2016). The PDT is predomi-
nantly selected as an outcome measure. Further-
more, the area of secondary hyperalgesia can be
quantified using mechanical (pinprick, stroking)
stimuli.
Critical Assessment of the Method
The heat burn model in combination with a
mechanical (pinprick) assessment of sensitization
is moderately sensitive to the effects of NMDA
receptor antagonists (Ilkjaer et al. 1996;
Mikkelsen et al. 1999). Analgesic effects of
other treatments are less conclusive. As an evoked
pain model, its principle is founded in controlled
tissue damage, by inducing a first-degree burn,
with reports of blistering in up to 20% of the
studies conducted with this paradigm (van
Amerongen et al. 2016). This may be considered
to be an advantage in terms of external validity.
However, from an ethical perspective a more
short-lasting model without actual tissue damage
may be preferred.
Modifications of the Method
The execution can vary from using a contact heat
thermode with a short and intense stimulus (100 s
at 50 C), to the more commonly used prolonged
exposure at lower temperature (7 min at 47 C).
Other heat sources, including laser stimulation or
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heat radiation, can be used. The arm or leg can be
used as location of exposure.
Lasers
Purpose and Rationale
Laser stimulation (LS) uses the energy to heat up
the epidermis and parts of the dermis with very
brief (range of ms) and powerful (8–200 mJ/mm2)
stimuli directed at the skin (Plaghki and Mouraux
2003). This type of stimulation causes a charac-
teristic double pain sensation, consisting of an
initial sharp pinpricking-like pain (Aδ-fibers)
and a second longer burning pain (C-fibers)
(Price 1996, 2000). Most commonly used laser
stimulators are based on CO2, Argon, and the
YAG (yttrium-aluminum-garnet).
Procedure and Evaluation
LS can stimulate the skin in a well-reproducible
manner making it useful as a tool to elicit evoked
potentials. Evoked potentials via EEG can easily
be registered due to the brief nature of the stimulus
of which the timing can be controlled as well.
EEG has been used in combination with laser
stimulation to distinguish between Aδ- and C-
nociceptive activities (Mouraux et al. 2003).
Critical Assessment of the Method
Importantly, during LS no (Aβ-fibers) tactile
mechanoreceptors are activated, making LS a use-
ful tool for investigating the nociceptive system
without the interference of non-nociceptive input.
However, due to the fast rise in temperature of the
skin, overstimulation may cause nociceptors to
become fatigued over repetitive stimuli
(Hüllemann et al. 2015). This in turn has an
unwanted effect on quantification of the nocicep-
tive system, as laser evoked potential habituation
may occur (Hüllemann et al. 2015; Treede et al.
2003). It is therefore advised to vary the stimula-
tion location slightly after each stimulus and use a
randomized inter-stimulus interval. Additionally
to habituation, precise settings are necessary to
prevent damage to the skin. Hence, power, dura-
tion, and surface area must be properly set up.
Modifications of the Method
LS stimulates both Aδ- and C-fibers by thermal
activation. However, adjusting the stimulation
method may shift the preferential activation of
either nociceptor. Preferential C-fiber stimulation
is based on a characteristic difference in heat
threshold (Aδ-fiber 46 C, C-fiber 40 C)
and distribution density in the upper skin (Ochoa
and Mair 1969). Shifting between Aδ and C-fiber
activation using LS is possible by choosing the
right pulse width, stimulation area in combination





Thermosensitive receptors located on muscle tis-
sue afferents are thought to be involved in ther-
moregulation (Hertel et al. 1976). As such, these
have been identified as potential targets to inves-
tigate nociception of deep muscle tissue. This is
investigated by exposing muscular tissue to a high
intensity thermal stimulation (Graven-Nielsen et
al. 2002). Only a single study was found using this
method.
Procedure and Evaluation
An intramuscular injection of sterile isotonic
(1.5 ml) heated saline is injected over 20 s
(270 ml h_1) into the musculus tibialis anterior.
Hyperalgesia can be quantified using a thermal
and mechanical stimulus.
Critical Assessment of the Method
Compared to hypertonic saline in the same study,
peak pain score resulting from intramuscular
injection of isotonic saline at different tempera-
tures was significantly lower. Mechanical sensiti-
zation appeared to be largest after injection at the
highest temperature (48 C). To avoid cutaneous
sensations, the injection site was anesthetized
with intradermal injections of 0.2 ml lidocaine
before the intramuscular injection (Graven-Niel-
sen et al. 2002).
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Modifications of the Method
In the single study using this method, intramuscu-
lar injections of isotonic saline at different tem-
peratures were investigated, ranging from 8 C to




Thermal stimulation of the GI tract activates spe-
cific nociceptive afferents selectively through
TRPV1. This is in contrast to mechanical and
electrical stimulation, which activate afferents
both superficial and deeper in the layers of the
viscera (Sengupta and Gebhart 1994). This makes
thermal stimulation of the GI tract a useful tech-
nique for specific activation of nonmyelinated
afferents in the mucosa.
Procedure and Evaluation
In several studies, a model was used to thermally
stimulate the esophagus (Arendt-Nielsen et al.
2009; Drewes et al. 2002, 2003b; Krarup et al.
2013). In these experiments, thermal stimuli were
performed by changing the temperature (5–60 C)
of recirculating water in a bag that was placed in
the lower part of the esophagus. Temperatures
were continuously measured inside the bag to
control the thermal stimulation in the esophagus.
Both for cold as for heat pain, a linear stimulus-
response (C-VAS) can be observed.
Critical Assessment of the Method
The upper GI tract (esophagus) is able to differ-
entiate between thermal stimuli in the temperature
range that can be used without chronic damage.
Quantification of the visceral pain is more difficult
to distinguish.
Modifications of the Method
It has been demonstrated that fast increases in
temperature (1.5 C/min) affect the precision of
the response (Olesen et al. 2010). Therefore, the
experimental esophageal model can be modified
by using slower temperature increases to ascertain
better results in pain assessments.
Electrical Stimulation
Electrical stimulation is used extensively for test-
ing the sensitivity of the pain system in studies
activating cutaneous structures, muscular struc-
tures, and in visceral structures (Andersen et al.
1994; Arendt-Nielsen et al. 1997; Laursen et al.
1997). Electrical stimulation initiates activity in
nerve fibers directly without activating receptors.
The stimulus intensity determines the size of the
current field in the tissue and thereby the number
of fibers activated (Andersen et al. 2001). In case a
rectangular pulse is applied to the skin, thick
fibers mediating mechanoreceptive input are acti-
vated at the lowest stimulus intensities. Increasing
the stimulus intensity leads to concurrent activa-
tion of thin myelinated fibers (Aδ-fibers) and
eventually C-fibers.
Electrical Skin Stimulation
Stimulation can be done cutaneous or intracuta-
neous with various stimulation paradigms with
diverse waveforms, frequencies, and durations to
selectively activate different afferents and nervous
structures and thereby evoke various pain sensa-
tions. In addition, summated neural activity, as a
result of the stimuli, can activate central mecha-
nisms (Koppert et al. 2001), which is described




This electrical stimulation paradigm leads to a
nociceptive, Aδ- and C-fiber mediated type of
pain, which is well controllable. The electrical
current stimulates nerve fibers directly because
the intensity is far below that required to stimulate
the actual receptors in the skin (Dotson 1997).
Procedure and Evaluation
For cutaneous electrical pain, two electrodes (Ag-
AgCl) are placed on clean (scrubbed) skin, e.g.,
the skin overlying the tibial bone. Electrical resis-
tance between electrodes should be less than 2 kΩ.
Each stimulus (10 Hz tetanic pulse with a duration
of 0.2 ms) is controlled by a computer-controlled
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constant current stimulator. Current intensity
increases from 0 mA in steps of 0.5 mA/s (cutoff
50 mA). The pain intensity after each stimulation
is measured using an (electronic) VAS, until pain
tolerance level is reached or a maximum of 50 mA
is reached (Olofsen et al. 2005).
Critical Assessment of the Method
Electrical stimulation is easily controlled. Electri-
cal stimulation of the skin to induce pain has
several shortcomings: (1) they excite the afferent
pathways in an unnatural synchronized manner;
(2) they excite the full spectrum of peripheral
nerve fibers (Aβ-, Aδ-, and C-fibers); and (3)
stimulation bypasses the receptors on the sensory
nerve endings, and therefore, all information on
specific activation and transduction processes is
lost (Handwerker and Kobal 1993).
Modifications of the Method
Aδ- and C-fibers are activated at different stimu-
lus intensities where C-fibers have a higher acti-
vation threshold. Modeling approach can be
useful for certain drug trials (Handwerker and
Kobal 1993; Lee et al. 2007). The nonspecificity
toward nociceptive specific stimulation is thought
to be overcome by using small specialized needle-
like electrodes. These electrodes slightly protrude
through the epidermis and can preferentially stim-
ulate nociceptive Aδ-fibers (Bromm and Lorenz
1984; Inui and Kakigi 2012;Mouraux et al. 2010).
Intracutaneous stimulation can be chosen to
mimic more a stinging/burning sensation and
less throbbing (Bromm et al. 1984b).
Electrical Burst (Temporal Summation)
Purpose and Rationale
Increasing pain in response to a series of stimuli
(temporal summation) reflects the first phase of
“wind-up” in animal studies. Temporal summa-
tion can be induced with mechanical, thermal, and
electrical stimulation (Arendt-Nielsen et al. 2000;
Granot et al. 2006; Mauderli et al. 2003; Nie et al.
2006). Temporal and spatial summation evoked in
the skin reflects a central nervous system modu-
lation of the response, and it is believed to mimic
neuropathic pain conditions because a likely
contribution of central sensitization to neuro-
pathic pain has been demonstrated (Woolf 2011).
Application of transcutaneous electrical stimuli,
with variation in electrical burst frequency, has
been shown to be a reliable model to induce
temporal summation in human subjects (Arendt-
Nielsen et al. 2000).
Procedure and Evaluation
For burst stimulus, each single stimulus is
repeated 5 times with a frequency of 2 Hz. Pain
threshold is taken as the value (mA) whereby a
subject indicates either: all 5 stimuli are painful, or
the train of 5 stimuli started feeling nonpainful but
ends feeling painful (VAS> 0) (Arendt-Nielsen et
al. 2000; Hay et al. 2016).
Critical Assessment of the Method
As facilitated temporal summation is a feature in
neuropathic pain patients, it has been hypothe-
sized that induction of temporal summation
using electrical stimulation can be used as a bio-
marker of drug effects on neuropathic pain
(Arendt-Nielsen et al. 2007b). In a recent study,
drug effects of analgesic compounds, including
several used in the treatment of neuropathic pain,
could not be established using this evoked pain
paradigm, while other evoked pain paradigms
manage to demonstrate pharmacological effects
convincingly. This appeared to be related to a
higher intra-subject variability that may necessi-
tate larger subject groups (Okkerse et al. 2017).
High-Frequency Electrical Stimulation
Purpose and Rationale
High-frequency electrical stimulation (HFS) of
the human skin induces increased pain sensitivity
in the surrounding unconditioned skin (Van den
Broeke et al. 2014). It has been shown that
sustained nociceptive input can induce activity-
dependent changes in synaptic strength within
nociceptive pathways, leading to an amplification
of nociceptive signals (Ikeda et al. 2003). This is
thought to play a key role in the development and
maintenance of chronic pain and in particular
some forms of hyperalgesia (Latremoliere and
Woolf 2009; Sandkühler 2009). HFS-induced
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hyperalgesia within the surrounding uncondi-
tioned skin mimics the phenomenon of secondary
hyperalgesia (Meyer and Treede 2004). As such,
it constitutes a suitable model to study the mech-
anisms underlying central sensitization of noci-
ceptive pathways (Klein et al. 2008).
Procedure and Evaluation
HFS is delivered to the test site, e.g., the volar
forearm, and consists of 5 trains of 100 Hz pulses
lasting 1 s, (10 s interstimulus interval; 2 ms single
pulse duration) at 10 times the detection threshold
(Pfau et al. 2011). The electrical stimulation is
generated by a constant-current electrical stimula-
tor and delivered to the skin using a specifically
designed electrode that has been demonstrated to
activate peptidergic nociceptive afferents in the
skin (Klein et al. 2004). The heterotopical effect
of HFS is usually characterized using mechanical
punctate stimuli. The test stimuli are applied to the
skin surrounding the area onto which HFS is
applied as well as to the same skin area on the
contralateral arm, which serves as control to take
into account a possible time-dependent habitua-
tion (van den Broeke et al. 2014).
The intensity of perception elicited by the three
types of test stimuli is assessed using a numerical
rating scale (NRS). After approximately 1 h, the
level of heterotopical hyperalgesia starts to dimin-
ish, however is still measurable and significant
from baseline up to 8 h after HFS (Pfau et al.
2011).
Critical Assessment of the Method
HFS offers an alternative to other models that lead
to secondary hyperalgesia, such as the capsaicin
model or the UVB model with some important
advantages. The major advantage versus the UVB
model is that the mechanism underlying the sec-
ondary hyperalgesia is thought to involve hetero-
synaptic facilitation and, hence, to constitute a
suitable model of central sensitization of nocicep-
tive pathways (Klein et al. 2008), while the sec-
ondary hyperalgesia in the UVB model is thought
to be due to a more peripheral sensitization of
nociceptors, induced by inflammation (Bishop et
al. 2009). The interval during which the secondary
hyperalgesia is measurable can be carefully
regulated and is relatively stable over the first
hour after application of HFS (Pfau et al. 2011).
The major disadvantage of this method is that is
has not been used to demonstrate pharmacody-
namic effects of analgesic drugs, although one
recent study did show that the model can be com-
bined with the assessment of drug effects (Vo et al.
2016).
Modifications of the Method
Modifications of the method are primarily related
to the type of sensory stimulus to determine the
heterotopical hyperalgesic effect and to the quan-
tification. Heterotopical hyperalgesia can be dem-
onstrated for mechanical punctate stimuli, but also
for thermonociceptive stimuli induced by heat
probes or laser stimulation. Van den Broeke et
al. used the model in conjunction to event related
potentials to objectively demonstrate the hyper-
algesic phenomena (Van den Broeke et al. 2014).
Electrical Muscle Stimulation
Purpose and Rationale
Electrical stimulation of muscle tissue can be used
to elicit both local and referred muscle pain. It
possesses the ability to generate referred muscle
pain in an “on and off”manner, and it is capable of
maintaining referred pain for at least 10 min
(Laursen et al. 1997). Intramuscular electrical
stimulation appears to be used more often to
study the nature of muscle pain than as a model
to determine the pharmacodynamic effects of new
analgesic compounds.
Procedure and Evaluation
In the intramuscular electrical stimulation para-
digm, two needle electrodes with uninsulated
tips are inserted into a muscle (e.g., the musculus
tibialis anterior). A computer-controlled constant
current stimulator is used to induce referred pain
in the ventral part of the ankle by stimulating the
muscle (Laursen et al. 1997). Each stimulation
consists of five constant current rectangular pulses
(1 ms) delivered at 200 Hz. The referred pain
threshold is defined as the lowest stimulus inten-
sity required for the subject to notice a “just barely
painful” sensation in the referred pain area.
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Referred pain thresholds are determined by a stair-
case regime consisting of five ascending and four
descending series of stimuli (Gracely 1994;
Laursen et al. 1997).
Critical Assessment of the Method
Electrical muscle and skin stimulation can use the
same modalities which makes it possible to com-
pare both models. A disadvantage of the model is
that referred pain due to intramuscular electrical
stimulation does not occur in all subjects; approx-
imately, three quarters of patients experience it
(Laursen et al. 1997). The referred pain typically
arises approximately 40 s after the onset of elec-
trical stimulation, which may mean that temporal
summation is involved (Laursen et al. 1997).
Modifications of the Method
Modifications can be made with the stimulation
settings. Pulse range of 100–200 Hz has been
described, as well as a pulse width of 1–2 s
(Laursen et al. 1997; van den Broeke et al. 2014).
Electrical Visceral Stimulation
In the viscera, it is difficult to determine the pain
threshold to a single stimulus, whereas the pain
threshold is easily determined if a train of stimuli
is used. Furthermore, the referred pain area grad-
ually expands if stimulation is continued for 120 s
(Arendt-Nielsen et al. 1997).
Chemical Stimulation
Administration of algonenic substances to the
skin, muscle, or viscera is believed to be a close
resemblance of clinical inflammation. Various
substances have been used to induce cutaneous
hyperalgesia. The most commonly used are cap-
saicin, nerve growth factor (NGF), glutamate,
mustard oil, andmenthol, but other chemical stim-
ulation models exist as well. Intramuscular injec-
tion of chemical substances is less common and
harder to control in a clinical trial. The esophagus
is the target organ when it comes to chemical




Capsaicin is a highly selective agonist for TRPV1,
notorious for its pungent property in red chili
peppers. TRPV1 channels are major transducers
of physically and chemically evoked sensations
(Hauck et al. 2015). The vanilloid 1 subtype is
activated by noxious heat ( 43 C) (Frølund and
Frølund 1986) and is expressed on C-fibers, and
on a subset of Aδ-fibers (Le Bars et al. 1979). The
direct effects of applying topical capsaicin are
burning sensations, hyperalgesia, allodynia, and
erythema. In addition, it triggers the release of
proinflammatory agents at peripheral terminals,
such as substance P and calcitonin gene-related
peptide (CGRP) (Kakigi 1994; Yarnitsky et al.
2010).
Procedure and Evaluation
Capsaicin can be administered topically and intra-
dermal. Intradermal injection with capsaicin
0.1 mg can cause hyperalgesia, but a dose of
100 mg or higher is needed to produce hyper-
algesia for an hour (Simone et al. 1987). A dose
of 100 mg is most frequently used (Baron et al.
1999; Serra et al. 1998; Torebjörk et al. 1992).
Topical administration of capsaicin in low con-
centrations (up to 3%) can cause temporary
mechanical and heat hyperalgesia. Sensitization
can be induced by preheating the skin to 45 C
for 5 min with a thermode directly before capsa-
icin application. Sensitization can be rekindled
throughout a study by reheating the skin up to
40 C for 5 min. Application of the capsaicin is
most commonly done on the forearm or the back,
but can be done on any area of the skin. Topical
application of capsaicin can induce peripheral and
central sensitization shown respectively by pri-
mary mechanical/thermal hyperalgesia and by
secondary mechanical hyperalgesia/allodynia.
This pain model can therefore be used to study
novel analgesic compounds targeting these typi-
cal symptoms of neuropathic pain. Peripheral sen-
sitization is caused by modulation of peripheral
afferents and is therefore restricted to the site of
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injury, i.e., primary hyperalgesia. Central sensiti-
zation is caused by modulation of the nociceptive
processing in the central nervous system. To
quantify the effects of this pain model, laser stim-
ulation (LS) can be used in combination with
electro-encephalogram (EEG).
Critical Assessment of the Method
Peripheral sensitization is closely linked to pri-
mary hyperalgesia, and central sensitization is
partly explained by hyperalgesia in the surround-
ing area, i.e., secondary hyperalgesia. Moreover,
nociceptive integration at spinal cord level may
include non-nociceptive mechanoreceptors.
Therefore, central sensitization may also cause
Aβ-fiber mediated pain (allodynia). Higher con-
centrations (capsaicin 8%) initially causes
increased sensitivity but is then followed by a
decrease in sensitivity due to a reduced TRPV1
expression (Messeguer et al. 2006; van
Amerongen et al. 2016). High concentration cap-
saicin is indicated in postherpetic neuralgia.
Besides, capsaicin may also have a neurolytic
property, where it (partly) eliminates epidermal
nerve fibers (ENFs) in treated areas over time
(Dworkin et al. 2010). Re-innervation occurs
over time (Hüllemann et al. 2015).
Modifications of the Method
There are several variations that need to be
addressed when designing a study utilizing cap-
saicin, e.g., concentration of the capsaicin, dose
administration (intradermal or topical), vehicle of
the capsaicin (alcohol or cream), duration of the
application, location of administration, and pre-/
rekindling.
Nerve Growth Factor Injection
Purpose and Rationale
NGF is a member of the neurotrophin family,
which also includes brain derived neurotrophic
factor (BDNF), neurotrophin-3 (NT3) and
neurotrophin-4/5 (NT4/5). NGF binds to both a
high affinity tyrosine kinase receptor trkA and a
low affinity receptor p75. NGF can sensitize
nociceptors so that they show an increased
response to thermal and chemical stimuli (Bennett
2007). Administration of NGF to human skin
evokes mechanical sensitization and profound
hyperalgesia to thermal stimuli that develops
within 3 h postinjection and peaks between day
1 and 7 (Dyck et al. 1997). Sensitization to heat
and hyperalgesia to cold develops within days
after injection and lasts up to 21 days, while
hypersensitivity to mechanical impact stimuli
develops over a longer period and persists for at
least 49 days (Rukwied et al. 2010). Intradermal
NGF administration provokes a pattern of sensiti-
zation that can be used as experimental model for
neuropathic pain (Rukwied et al. 2010).
Procedure and Evaluation
One microgram of human recombinant lyophi-
lized NGF is dissolved in 50 μL saline and
injected intradermally into the central volar fore-
arm. The same volume of saline is administered
into the contra-lateral site as vehicle control
(Rukwied et al. 2010). Vasodilatation upon
NGF- and saline-injection can be recorded by
laser Doppler imaging. Nociceptor sensitization
can be explored to mechanical (touch, pinprick,
pressure), thermal (cold, heat), and electrical (cur-
rent pulses) stimuli. Stimuli for investigating
static and dynamic allodynia and pinprick hyper-
algesia are administered 5–7 cm distal from the
injection site and continued in steps of 1 cm until
the subject reports a definite increase of pinprick
pain or switch from touch to an aversive sensation
(Rukwied et al. 2010). The point where this starts
is marked on the skin and the distance to the
injection site measured. Pain thresholds and sub-
jective scores with NRS/VAS can be used to eval-
uate the mechanical, thermal, or electrical
stimulation.
Critical Assessment of the Method
Increased levels of NGF have been reported in
human painful disorders including arthritis (Kidd
and Urban 2001). Injection of NGF therefore
appears to mimic processes found in clinical dis-
ease (Olesen et al. 2012). Even though NGF may
also be upregulated in the UVB burn (Bishop et al.
2007), anti-NGF has been shown to only partially
reduce UVB induced hyperalgesia (Bishop et al.
2007). Apparently, the NGF induced mechanism
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of mechanical sensitization is different to UVB
evoked primary hyperalgesia. NGF induces a par-
ticularly long lasting mechanical sensitization
including static allodynia and cold hyperalgesia
without any visible signs of inflammation and
therefore adds to the spectrum of human evoked
pain models (Rukwied et al. 2010). The long-
lasting local allodynia and hyperalgesia after sub-
cutaneous or intradermal injection, up to 49 days
after injection, form the most important disadvan-
tage of the model. Even though considered a
model for neuropathic pain, it is unlikely that
central sensitization plays a role.
Modifications of the Method
Systemic administration of NGF 1 μg/kg i.v. has
been shown to lead to mild to moderate muscle
pain mainly in the bulbar and truncal musculature
that lasted 2–8 days (Petty et al. 1994).
NGF has been injected into the musculus mas-
seter to induce allodynia and hyperalgesia and as a
model of myofascial temporomandibular disorder
pain (Svensson et al. 2003).
Other Chemical Mediated Models
Mustard Oil
Mustard oil is a plant-derived irritant. The noxious
effects of mustard oil are currently ascribed to
specific activation of the cation channel transient
receptor potential, subfamily A, member 1
(TRPA1) in nociceptive neurons (Olesen et al.
2012). Topical administration leads to a burning
pain in the area exposed to mustard oil as well as
secondary allodynia and hyperalgesia in the sur-
rounding unaffected area, similar to the topical
capsaicin model (Koltzenburg et al. 1992).
Menthol
Menthol acts as an agonist on the transient recep-
tor potential cation channel subfamily M member
8 (TRPM8) receptor. The topical application of
high concentration (40%) menthol is thought to
activate and sensitize cold-sensitive TRPM8-
expressing C-nociceptors and activates cold-spe-
cific Aδ-fibers (Binder et al. 2011). Topical
application has been used as an evoked pain
model of cold hyperalgesia, which is a clinical
symptom that occurs frequently in patients with
peripheral or central nervous system lesions
(Hatem et al. 2006). In addition to cold hyper-
algesia, the model elicits primary and secondary
mechanical (pinprick) hyperalgesia combined
with the sensation of burning (Binder et al.
2011). The menthol model has been shown to be




Intramuscular injection with NGF is most com-
monly done in the musculus tibialis anterior or
musculus masseter (Andersen et al. 2008;
Svensson et al. 2008). It induced a long-lasting
hyperalgesia and lower pressure pain threshold
can be observed, lasting up to 4 days in the
musculus tibialis anterior and up to 14 days in
the musculus masseter (Andersen et al. 2008;
Svensson et al. 2008). An advantage of the intra-
muscular NGF paradigm is the long-lasting
hyperalgesia which can simulate clinical pain
more than most other paradigms, but this is also
the disadvantage where ethical consideration may
play a role. The paradigm is difficult to control
where hyperalgesia is dependent on the dose and
the size of the muscle (Andersen et al. 2008).
Chemical Visceral Stimulation
Esophagal (Gut) Perfusion with Acid,
Alcohol, Glycerol, Capsaicin, and Hypertonic
Saline
Purpose and Rationale
Chemical stimulation of the GI tract may be used
to stimulate C-fibers selectively via TRPV1 recep-
tors and modulate the visceral pain system due to
their sensitization effects. Having a model of cen-
tral sensitization of the viscera can be helpful in
the development of new analgesics, as this is
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thought to be an important element of chronic
visceral pain.
Procedure and Evaluation
Using acid to stimulate the esophagus is the most
used method to sensitize the gut (Bernstein and
Baker 1958; Demedts and Tack 1998; Drewes et
al. 2005; Reddy et al. 2005). However, other
chemicals such as alcohol, glycerol, capsaicin,
and hypertonic saline are used to stimulate the
gut as well (Louvel et al. 1996; Drewes et al.
2003a, b). The chemical compound is usually
infused into a container/bag residing in the esoph-
agus with a small perfusion hole to release the
compound into the esophagus. Chemical stimula-
tion is able to modulate the visceral pain system
by selectively activating nonmyelinated C-fibers
for a longer amount of time. This tonic activation
may result in central sensitization effects, which
can be quantified by subsequent thermal, electri-
cal, or mechanical stimulation.
Critical Assessment of the Method
A high variation in the outcome measures is seen
with this model. The reproducibility is challeng-
ing because several factors are hard to control, like
exposure time to the chemical stimulus, size of the
treated area, and latency time to onset of effects.
Furthermore, tissue injury results in the release of
multiple molecules working together, and to
mimic this situation it may be necessary to use a
mixture of chemical substances (Reddy et al.
2005). Blinding this procedure is difficult, since
subjects are able to taste the compound. There-
fore, the experimental setup requires that both
subject and assessor are ignorant of the possible
influence of the compound on the pain threshold
(Drewes et al. 2003b).
Modifications of the Method
Each chemical substance will have an impact on
the results. For example, the motility may inter-
fere with the results when glycerol is used. Other
stimuli, such as injection of hypertonic saline and
application of capsaicin, the pain is elicited
shortly after the chemical comes into contact
with the mucosa, and the motility has minor
impact on the results.
Discussion
Healthy Subjects Versus Patients
Despite many advances in the last decades in
understanding pain, the development of new anal-
gesic compounds lacked behind. In almost
60 years, only 59 compounds were registered for
the treatment of pain, of which two thirds were
specifically developed as analgesics (Kissin
2010). Historically, pain states have been classi-
fied and investigated on the basis of a disease
state. Based on preclinical animal models, target
patient populations were selected. In patient stud-
ies, efficacy is then reported as change in the
patient’s response to pain (McQuay and Moore
2013). Unfortunately, several promising com-
pounds have failed in this late-stage development
where pharmacotherapy only provides meaning-
ful pain relief in less than 50% of patients with
neuropathic pain (Finnerup et al. 2010, 2015). But
a negative outcome does not automatically mean
inefficacy of the compound. Pathophysiological
mechanisms of pain vary between individuals
with the disease state. Selecting and clustering
the patients in groups of pathophysiology rather
than disease might be necessary to obtain mean-
ingful results. The use of human evoked pain
models can provide more information.
Multimodal testing in healthy volunteers can
provide information about the analgesic activity
of the compound and possibly find the active dose
level range. In a way, by using different pain
modalities, the results will create a certain pain
profile of the compounds (Okkerse et al. 2017).
These results may reflect effects of analgesic
drugs on mechanisms involved in clinical pain.
Thus, multimodal pain testing may aid in deter-
mining the optimal target population for new anal-
gesic compounds based on their profile of effects
on a diversity of pain mechanisms and depending
on the contribution of each of these mechanisms
in clinical pain phenotypes. In several chronic
pain populations, such as chronic whiplash, rheu-
matoid arthritis, vulvodynia, and fibromyalgia,
changes in pain tolerance levels, pain modulation,
and augmented brain responses and altered
responses to analgesics have been found (Daenen
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et al. 2014; Hampson et al. 2013; van Laarhoven
et al. 2013). Using evoked pain in these patients
can provide insight into the analgesic mechanisms
– or lack thereof – in these altered pain states
(Olesen et al. 2012). In patients with chronic (neu-
ropathic) pain, different sensory profiles exist.
These profiles possibly match with different neu-
robiological mechanism of pain (Baron et al.
2017).
Predictive Value of Models for Drug
Development
Human evoked pain models in healthy volunteers
can be conducted in standardized laboratories.
Factors like stimulus intensity, frequency, dura-
tion, and location can be controlled, and when a
model is stable and reproducible, it can be
regarded as suitable for pharmacodynamic evalu-
ation of new analgesic drugs. Using pain models
in healthy volunteers has important advantages
over assessing the effects of new drugs in patients
with pain; the pain elicited in human pain models
is predictable in its intensity while clinical pain
will naturally fluctuate, and in pain models anal-
gesic properties can be investigated without the
influence of accompanying symptoms that are
often seen in patients with pain. However, it
should always be asked whether a pain model at
all resembles naturally occurring pain. Clinical
pain is a subjective perception, influenced by cog-
nitive processes, by emotions, social context, and
even cultural background, while pain models are
solely based on the infliction of a noxious stimu-
lus and its response. An important question is
whether or not a positive result in a certain evoked
model is also predictive of clinical efficacy.
Two approaches have been used to investigate
this. Moore and colleagues investigated which
naturally occurring pain was physiologically
most in agreement with evoking a pain response
causing the same type of pain. For instance, they
concluded that intramuscular electrical stimula-
tion closely matched clinical acute musculoskele-
tal pain (Moore et al. 2013). Oertel and Lötsch
evaluated the differences between human pain
models and clinical efficacy. First they looked at
which drugs were effective in different pain con-
ditions (e.g., NSAIDs were effective for inflam-
matory arthritis), then they investigated which
drugs were effective in which pain model (e.g.,
NSAIDs influence pain response in laser evoked
pain). If a certain drug was effective both in the
model and in the particular clinical setting, the
model was concluded to possibly be predictive
for the type of clinical pain. Some level of agree-
ment could be observed for a large number of pain
models with many different clinical forms of pain
(Oertel and Lötsch 2013). In another review, the
mutual agreement between pain models and clin-
ical efficacy was statistically assessed. It was
observed that a small set of pain models seemed
predictive for efficacy in the clinic, for example,
capsaicin induced hyperalgesia with mechanical
stimulation is associated with trigeminal neuralgia
and renal colic, and UVB induced hyperalgesia in
combination with heat stimulation can be linked
to burn injuries or postoperative pain (Lötsch et al.
2014).
Several reviews investigated which evoked
pain models were sensitive to the analgesic effects
of different classes of analgesics in healthy sub-
jects (Oertel and Lötsch 2013; Okkerse et al.
2017; Staahl et al. 2009a, b). With the aid of
these studies, well-considered decisions can be
made on which evoked pain models to include in
studies investigating potentially analgesic
compounds.
Multi-model Assessment of Pain
Pain comes in various types and can originate in
many different tissues. It is obvious that different
analgesics will influence different types of pain
according to their respective mechanism of action.
If an analgesic drug with a novel mechanism of
action is studied, it can occur that a single pain
model, thought to relate to a specific clinical pain
syndrome, demonstrates lack of efficacy of the
new compound. In these cases, a combination of
human evoked pain models can be used to screen
for possible analgesic effects of these compounds.
For instance, a combination of a mechanical, ther-
mal, and electrical pain models: pressure
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stimulation assesses the nociception generated
from within the muscle (Polianskis et al. 2001);
cold pain induced by the cold pressor test mainly
activates C-fibers in the skin (Olesen et al. 2012);
heat stimulation initially activates Aδ-fibers in the
skin, followed by C-fiber activation; induction of
inflammation via sunburn or UVB induces the
production of cytokines that lead to sensitization
of cutaneous nociceptors (Bishop et al. 2009); and
electrical stimulation directly stimulates sensory
nerve endings of both Aδ and C-fibers in the skin
(Handwerker and Kobal 1993). This multimodal
testing with a battery of different pain models has
been performed by multiple study groups
(Enggaard et al. 2001; Okkerse et al. 2017; Olesen
et al. 2014; Staahl et al. 2006). The batteries have
in common that they induce pain via different
modalities and in different tissues and mimics
clinical pain better than a single pain model can.
The multimodal batteries can be used to profile the
analgesic effects of new drugs, to obtain the opti-
mal dose of new analgesics, and to benchmark
new drugs against profiles of well-known analge-
sics (Okkerse et al. 2017).
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